🇺🇸 FDA
Pipeline program

RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion

BP41072

Phase 2 small_molecule active

Quick answer

RoActemra 20 mg/mL concentrate for solution for infusion, CD19 4-1 BBL, Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials